drugset / Trial / NCT03736369

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

NCT03736369

Phase 3 Completed 263 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.

Timeline

Start
2018-12-13
Primary completion
2019-08-07
Completion
2019-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule 40 mg Oral
Comparator Esomeprazole Small molecule 40 mg Oral

Indications